What AEON Biopharma Inc.’s analytical strategy reveals about the future of botulinum toxin biosimilars

AEON Biopharma advances ABP-450 biosimilar strategy. Discover what this means for BOTOX competition and future complex biologics markets.

AEON Biopharma advances ABP-450 biosimilar strategy. Discover what this means for BOTOX competition and future complex biologics markets.